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Macrophages are extremely versatile cells that adopt a distinct phenotype in response to
a changing microenvironment. Consequently, macrophages are involved in diverse func-
tions, ranging from organogenesis and tissue homeostasis to recognition and destruction
of invading pathogens. In cancer, tumor-associated macrophages (TAM) often contribute to
tumor progression by increasing cancer cell migration and invasiveness, stimulating angio-
genesis, and suppressing anti-tumor immunity. Accumulating evidence suggests that these
different functions could be exerted by specializedTAM subpopulations. Here, we discuss
the potential underlying mechanisms regulating TAM specialization and elaborate on TAM
heterogeneity in terms of their ontogeny, activation state, and intra-tumoral localization. In
addition, parallels are drawn between TAM and macrophages in other tissues. Together, a
better understanding of TAM diversity could provide a rationale for novel strategies aimed
at targeting the most potent tumor-supporting macrophages.
Keywords: tumor-associated macrophage, TAM heterogeneity, macrophage ontogeny, macrophage proliferation,
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INTRODUCTION
Cancer cells are confronted with cells of the immune system
throughout all phases of the disease, from early carcinogenesis to
tumor progression and metastasis. In this respect, macrophages
play a prominent role and have been shown to actively con-
tribute to each cancer stage (1, 2). During chronic inflamma-
tions, driven for example by auto-immunity or persistent infec-
tions, macrophages play a central role as perpetuators of the
disease, thereby producing cytotoxic and mutagenic compounds
(for example, reactive oxygen and nitrogen species) that cause col-
lateral damage to the surrounding tissue, leading to carcinogenesis.
At metastatic sites, macrophages also cross-talk with the surround-
ing tissue, priming it for the arrival of circulating cancer cells and
aiding those cancer cells to invade the metastatic niche (1). How-
ever, most evidence is available for a tumor-promoting role of
macrophages within the primary tumor microenvironment.
The ecosystem of solid tumors is quite dynamic and complex,
encompassing multiple non-transformed cells that are essential for
the organoid behavior of a tumor. These cells include fibroblasts –
responsible for the production of extracellular matrix, endothelial
cells (EC) – responsible for blood vessel formation, and multiple
hematopoietic cell types. The immune composition (also termed
the immune contexture) of a tumor, primarily defined as the type,
density, functional orientation, and location of adaptive immune
cells, changes at each tumor stage and can independently predict
disease outcome (3, 4). In particular, signatures associated with
Th1 and cytotoxic T-cell responses predict a prolonged disease-
free survival (3). In addition, tumors contain sizeable populations
of myeloid cells, including neutrophils, eosinophils, dendritic cells,
and especially macrophages. In extreme cases, tumor-associated
macrophages (TAM) could represent up to 50% of the tumor
mass. For long, this was considered to be an indication of anti-
tumor immunity considering the inherent phagocytic and cyto-
toxic properties of macrophages. By now, it is clear that these
protective properties of macrophages are suppressed in the tumor
microenvironment and can only be reinvigorated upon thera-
peutic intervention. For example, macrophage-mediated cancer
cell phagocytosis, resulting in tumor shrinkage, can be restored
upon blockade of CD47, a “don’t eat me” signal overexpressed by
most cancer cells (5). Along the same line, macrophage-dependent
tumor cytotoxicity via nitric oxide can be stimulated by IL-2/anti-
CD40 immunotherapy (6). However, when untreated, a significant
link between TAM number/density and a poor prognosis becomes
evident in most tumor types, illustrating the clinical significance of
these cells (7, 8). This is mechanistically explained by the contribu-
tion of TAM to cancer cell invasion and metastasis, to angiogenesis,
and to immunosuppression [reviewed in Ref. (1, 9)]. Moreover,
TAM contribute to tumor relapse following tumor irradiation, the
administration of anti-angiogenic, and vascular-disrupting agents
and some forms of chemotherapy (10, 11). Thus, it becomes clear
that dynamic changes in the phenotypes of macrophages occur
during tumor initiation, progression, and metastasis and that sub-
populations of TAM are responsible for distinct tumor-promoting
activities (1, 2, 12). However, several open questions remain on the
mechanisms behind the generation of TAM subsets that are cru-
cial for defining therapeutic approaches in cancer: which is the
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network of signaling molecules, transcription factors, epigenetic
mechanisms, and posttranscriptional regulators that underlie the
different activation states? Do these activation switches involve
recruitment of circulating precursors or the re-education of cells
in situ? How reversible is TAM polarization?
In this review, we discuss several of these mechanisms and
open questions, and we draw parallelisms with macrophages asso-
ciated with other tissues in pathological and non-pathological
conditions.
TAM DIVERSITY IN TERMS OF ONTOGENY
Peripheral blood monocytes were long thought to be obliga-
tory intermediates in the differentiation of tissue macrophages.
However, recent evidence demonstrated that several, if not most,
organ-resident macrophages originate early in life, either during
embryogenesis or shortly after birth. Indeed, fate mapping analyses
revealed that liver Kupffer cells (KC), lung alveolar macrophages,
peritoneal macrophages, epidermal Langerhans cells, and brain
microglia were derived from primitive precursors and were self-
maintained locally under steady state without a significant input
from circulating monocytes (13–17). The exact nature of this
primitive precursor is still a matter of some debate and includes
fetal liver monocytes (15, 17) and yolk sac-derived macrophages
(18). Obviously, cancer is a deviation from the steady state and
it is therefore unclear to what extent bona fide tissue-resident
macrophages contribute to tumor development and progression.
Solving this issue is not trivial considering the paucity of mark-
ers to discriminate between tissue-resident and tissue-recruited
macrophages.
EVIDENCE FOR THE INVOLVEMENT OF TISSUE-RESIDENT
MACROPHAGES IN CANCER
In this section, we will focus on the role of KC and microglia dur-
ing hepatocellular carcinoma (HCC) and glioma development and
progression, respectively. These two cases illustrate the complexity
of analyzing macrophage ontogeny during cancer and could be
exemplary for tumors in other organs.
During diethylnitrosamine (DEN)-induced hepatocarcinogen-
esis, KCs were reported to stimulate tumorigenesis through the
activation of pro-inflammatory receptors such as TREM-1 (19)
and the secretion of hepatomitogens such as TNF and IL-6 (20).
As a matter of fact, in this model, the gender differences in tumor
incidence are dependent on the estrogen-regulated difference in
IL-6 production by male versus female KCs (21). Though origi-
nally thought of as a non-inflammatory regimen, it is now clear
that DEN treatment provokes local and systemic inflammatory
responses characterized by the intrahepatic induction of distinct
inflammatory chemokines and influx of macrophages and T cells
(22). It remains therefore unclear whether DEN-mediated hepa-
tocellular carcinogenesis truly relies on tissue-resident KCs or
rather on liver-recruited macrophages. In established HCC tumors
from patients, CD68+ monocytes/macrophages were amongst
the most abundant inflammatory cells, comprising two main
subpopulations: small HLA-DRhigh IL-10low cells in peritumoral
stroma, reminiscent of newly recruited monocytes, and larger
HLA-DRlow IL-10high cells in cancer nests resembling mature
macrophages (23). These populations were suggested to promote
tumor progression by fostering immune privilege through the
expression of PD-L1 (24, 25) and the induction of regulatory
T cells (Treg) (26). However, whether any of these populations
comprise KCs is questionable. Indeed, when applying rather strict
parameters for the identification of these cells (CD68+, present in
the blood space of cancer tissue, stellate or spindle shape), it turns
out that KCs are underrepresented in cancerous tissue compared
to adjacent healthy tissue and their numbers steadily decrease in
later tumor stages (27). Finally, evidence exists for the implication
of KCs in liver metastasis formation by colorectal cancer (CRC)
cells (28). When CRC cells escape the primary tumor, they typically
end up in the portal vein and the liver sinusoids, where they are
confronted with KCs. On the one hand, KCs might present tumo-
ricidal activity thereby limiting metastasis. However, when cancer
cells are not immediately killed (for example, if too many of them
arrive in the sinusoids and KCs become saturated) KCs might actu-
ally promote metastasis by trapping CRC cells and activating the
endothelium for extravasation.
In the brain, microglia can mitigate the tumor-forming capac-
ity of brain tumor initiating cells (BTIC) that contribute to the
genesis or recurrence of gliomas, but that capacity is lost when
tumors become established (29). At that later stage, microglia
are able to stimulate glioblastoma cell invasion via epidermal
growth factor (EGF) secretion (30). Similarly, during glioma
progression, TAM contribute to tumor expansion via MT1-
MMP (31), but the relative contribution of microglia versus
bone marrow-recruited macrophages is unclear. Both popula-
tions are indeed present in gliomas, rather vaguely described
as CD11b+CD45low (for microglia) and CD11b+CD45high (for
recruited macrophages) illustrating that these cells are difficult to
discern (32). In fact, a surface marker was identified – F11R –
that typifies glioma-associated macrophages irrespective of their
ontogeny (33), suggesting that the tumor microenvironment
might overrule ontogenic differences.
In conclusion, both tissue-resident and -recruited macrophages
might coexist in tumors, but their respective contribution to vari-
ous aspects of tumor progression and dissemination remains to be
established and awaits better tools to discern ontogenically distinct
macrophage populations.
EVIDENCE FOR THE INVOLVEMENT OF TISSUE-RECRUITED
MACROPHAGES IN CANCER
As mentioned in the previous section, bone marrow-derived prog-
enitors can contribute to the TAM population. This is expected
to be especially prominent under (chronic) inflammatory con-
ditions and injury, during which the tissue macrophage pool is
typically reinforced by the influx of monocytes, as demonstrated
in liver (34), skin (35, 36), brain (37), colon (38), and other
tissues. Peripheral blood monocytes consist of two main popu-
lations, known as inflammatory or classical monocytes (Ly6Chigh
CX3CR1low CCR2high in mouse and CD14++CD16− in man)
and patrolling or non-classical monocytes (Ly6Clow CX3CR1high
CCR2low and CD14+CD16++), whereby the patrolling popula-
tion can be derived from inflammatory monocytes (38). Cur-
rent evidence suggests that the inflammatory/classical monocytes
are rapidly recruited into inflamed tissues, while patrolling/non-
classical monocytes rather survey the intravascular vessel wall and
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mediate the elimination of stressed or damaged EC (39). How-
ever, in some pathologies, patrolling monocytes do make it into
the tissues, where they rather contribute to a healing response (40).
Tumors have been described as “wounds that do not heal”
(41) and are often linked with chronic inflammation, resulting
in a prominent monocyte infiltration in the tumor microen-
vironment. However, the monocyte subset that is recruited to
the primary tumor and the involvement of the CCL2-CCR2
chemokine axis in this phenomenon appears to be model- and
tumor type-dependent. In the case of transplantable mammary
and lung carcinomas, a CCR2-driven recruitment of Ly6Chigh
monocytes gives rise to different TAM subpopulations (42–45)
Similar findings were obtained in the K14-HPV/E2 transgenic
model of cervical carcinogenesis (46) and a KrasLSL/G12D/+; p53fl/fl
conditional genetic mouse model of lung adenocarcinoma (47).
Moreover, inflammatory monocyte recruitment to human pan-
creatic tumors decreases patient survival, in agreement with the
fact that patients with tumors that exhibit high CCL2 production
have a worse prognosis (48). CCL2-mediated monocyte recruit-
ment to the tumor is also important in patients suffering from
follicular lymphoma (49). Overall, a high CCL2 expression level
is correlated with a worse outcome in many cancer types, sug-
gesting that CCR2+ inflammatory monocytes often function as
tumor-promoting cells. An interesting issue is the origin of these
tumor-infiltrating monocytes. The bone marrow is classically seen
as the major source of peripheral blood monocytes, whereby CCR2
is critical for Ly6Chigh monocyte emigration to the blood (50).
Recently, however, the spleen was discovered as a reservoir for
monocytes that can be mobilized in case of emergency. During
tumor growth, angiotensin II overproduction drives hematopoi-
etic stem cell retention in the spleen and the local differentiation
of monocytes (51). Subsequently, splenic Ly6Chigh monocytes
are recruited to the tumor in a CCL2/CCR2-dependent fashion,
where they contribute significantly to the TAM pool and tumor
progression (47). In the MMTV-PyMT transgenic model of mam-
mary adenocarcinoma development, Ly6Chigh monocytes are only
recruited to lung metastases where they promote extravasation of
cancer cells, whereas primary tumors are infiltrated with Ly6Clow
monocytes (52). Alternatively, a sequential infiltration of both
monocyte subsets during distinct tumor stages is also possible, as
shown in the ID8 ovarian carcinoma model (53). Finally, it should
be noted that monocytic myeloid-derived suppressor cells (MO-
MDSCs) strongly resemble Ly6Chigh monocytes (54). Within the
tumor, MO-MDSCs rapidly differentiate into macrophages when
exposed to hypoxia, in a HIF-1α-dependent way (55).
EVIDENCE FOR THE INVOLVEMENT OF INTRA-TUMORAL TAM
PROLIFERATION
Self-maintenance of tissue-resident macrophages is the conse-
quence of low-grade proliferation. The proliferation rate of these
cells can be enhanced by CSF-1/M-CSF and/or IL-4 under con-
ditions of helminth infection (56, 57), a healing response (58),
atherosclerosis and possibly other types of inflammation. Remark-
ably, relatively little information is available on the proliferative
capacity of TAM. In the transplantable Lewis lung carcinoma and
TS/A breast carcinoma models, cell cycle analysis did not reveal sig-
nificant levels of TAM proliferation (42, 44). In the former model,
parabiotic experiments demonstrated that the tumor microen-
vironment may support monocyte/macrophage survival, rather
than proliferation (45). However, one study in human breast can-
cer patients established the presence of PCNA+CD68+ cells in
tumors, suggestive of proliferating TAM (59). Proliferating TAM
were significantly correlated with high grade, hormone receptor
negative tumors, and a basal-like subtype, and were predictors of
recurrence and survival. It is therefore conceivable that TAM pro-
liferation becomes more prominent if tumor inflammation and
the rate of monocyte influx are less prominent.
TAM DIVERSITY IN TERMS OF ACTIVATION STATE
Macrophages demonstrate a high degree of plasticity in response to
local cues from the microenvironment and can assume a spectrum
of roles required for tissue homeostasis, ranging from host defense
against infectious agents, to tissue development, wound healing,
and immune system regulation (60). Macrophage activation was
originally categorized on a linear scale, where the two extremes
were the classically activated pro-inflammatory M1 macrophages,
induced by IFNγ and toll-like receptor (TLR) ligands (M1),
and the alternatively activated anti-inflammatory macrophages,
induced by IL-4/IL-13, mirroring and mediating the polarized
Th1-Th2 responses, respectively [reviewed in Ref. (60–62)]. The
M1/M2-classification, although conceptually useful, tends to over-
simplify the functional diversity of macrophages (63, 64). It has
been proposed that macrophages can also undergo innate activa-
tion (TLR ligands without IFNγ), leading to pro-inflammatory but
poor antigen presenting cells, or turn into regulatory cells (TLR
ligands with anti-inflammatory mediators such as prostaglandins
or immune complexes) that are IL-10highIL-12low but good antigen
presenters (65, 66). Along the same line, an alternative macrophage
classification has been proposed, based on the three fundamental
macrophage functions that are involved in maintaining homeosta-
sis: host defense, wound healing, and immune regulation. These
three basic types of macrophages would be able to blend into many
other “shades” of activation that remain to be identified (64).
EVIDENCE FOR DIFFERENTIALLY ACTIVATED TAMWITHIN TUMORS
Clearly, cells of the monocyte/macrophage lineage are character-
ized by their high diversity and plasticity. According to a model
of functional adaptivity proposed by Stout et al., macrophages
are capable not only of adapting to microenvironmental signals
by mounting different functional patterns, but also of changing
their functional phenotype in response to progressive variation
of these signals (67). In cancer, too, it is becoming clear that
macrophages are heterogeneous and, depending on the tissue and
type of tumor, the stage of tumor progression and location within
the tumor tissue, different subpopulations of macrophages may
differ considerably in terms of function and M1/M2 phenotype
(2, 68–70). Firstly, macrophages in their capacity of prominent
inflammatory M1 cells play a non-redundant role during chronic
inflammation-associated carcinogenesis. For example, blocking
the CCL2-mediated recruitment of macrophages to the chroni-
cally inflamed colon resulted in a reduction of colitis-associated
carcinogenesis (71). Along the same line, CCL2 upregulation by
prostaglandin E2 during Helicobacter pylori infection is needed
to recruit macrophages to the stomach and initiate gastric tumor
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formation (72). Interestingly, during skin carcinogenesis, fibrob-
lasts were shown to be obligatory for maintaining the CCL2-
mediated recruitment of macrophages (73). Inflammatory and
anti-inflammatory signaling pathways determine the carcinogenic
potency of macrophages. Indeed, a myeloid cell-specific deficiency
in NF-κB activity reduces tumor formation (74), while a myeloid
cell-specific deficiency of STAT3 results in the spontaneous devel-
opment of colitis triggered by the gut microflora and leads to an
enhanced rate of tumor formation in inflamed regions (75).
Also in established tumors, macrophages may promote the pro-
gression of the disease. This is exemplified by the fact that TAM
presence is correlated with poor prognosis in many types of can-
cers, such as Hodgkin lymphoma, glioma, cholangiocarcinoma,
and breast carcinoma (7, 76–79) while some exceptions like colon
cancer (80, 81) have been reported. In fact, more recent research
has suggested that the phenotype and activation state of TAMs,
rather than their absolute number, is more informative for patient
prognosis (82). For instance, infiltration of CD40+ macrophages
in CRC and of CD14+CD163− macrophages in cervical cancer
were associated with a favorable prognosis (81, 83). As stated ear-
lier, it is still not fully resolved whether TAM diversity results from
the maturation of unique monocytic precursors or from differ-
ences in micro-anatomical factors (42). However, it is highly likely
that the different activation states of TAM subsets reflect responses
to dynamic local microenvironmental cues within the tumor.
The activation state of macrophages in cancer depends on the
stage of tumor development. Indeed, at least in some models
of carcinogenesis in the mouse, tumor progression is associated
with a phenotypic switch from M1 to M2 macrophages (84).
This has led to the consensual view that, in sites of chronic
unresolved inflammation, macrophages initially triggered by a
pathogen or tissue stress, recruit monocytes that develop into
additional inflammatory M1-like macrophages. While this may
initiate the first steps of carcinogenesis, as discussed in the pre-
vious chapter, the inflammatory cascade may also contribute to
the T-cell-mediated elimination and equilibrium phases during
tumor progression (85). At later stages of tumor progression,
recruited monocytes differentiate into macrophage subpopula-
tions with an overall more M2-like, wound healing or “trophic”
phenotype (low IL-12 expression, high IL-10 expression, and low
tumoricidal activity) that promotes tissue remodeling and angio-
genesis (1, 86). However, it should be realized that within these
more M2-oriented cells, subpopulations exist with a somewhat dif-
ferent activation profile (42–44). In any case, a dynamic activation
switch occurs among TAMs as the tumor develops, which may help
explain the “mixed” activation state of TAM populations found in
different established murine and human tumors (87–89). Alterna-
tively, macrophages within established tumors may be exposed to
opposing signals that underlie the different TAM activation states
and subpopulations found within the same tumor (Figure 1).
Various pathways orchestrate the function of myelomonocytic
cells, and are induced by signals from the tumor itself and from
the stroma (such as fibroblasts and infiltrating leukocytes). These
signals include:
FIGURE 1 |Tumor-associated macrophage heterogeneity depends
on ontogeny, activation, and localization. TAM are heterogeneous
depending on their: (i) ontogeny, (ii) activation, or (iii) localization. (i) TAM
could either be derived from the self-renewing tissue-resident
macrophage pool (tissue-resident TAM), whose precursors are formed
early in life in the yolk sac or fetal liver; or can be derived from
circulating monocytes, termed tissue-recruited TAM. In addition,
maintenance or accumulation of TAM could be due to proliferation in
the tumor. (ii) Depending on the signals, they receive from their
microenvironment, TAM can be either more M1 or M2 activated or
display a mixed activation state. (iii) In addition, the localization of TAM
can play a role in their phenotype. For example, molecular and
functional differences are observed between TAM residing in normoxic
perivascular areas or hypoxic areas.
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MYELOPOIETIC GROWTH FACTORS
M-CSF (CSF-1) instructs the myeloid fate in hematopoietic stem
cells and remains instrumental for the generation of monocytes
and macrophages (90). Notably, M-CSF-driven macrophage dif-
ferentiation leads to the expression of a substantial part of the
M2 transcriptome, including expression of mannose receptor 1
(Mrc1 or MMR) and scavenger receptor A (SR-A), while GM-CSF
(CSF-2) rather induces an M1-type of activation (91–93).
A M-CSF response signature is often observed in primary
tumors and corresponding metastases, correlating with tumor
grade and worse prognosis (94–96). Accordingly, recent studies
have reported high expression of M-CSF in peritumoral liver tis-
sue, which was associated with macrophage density, intrahepatic
metastasis, and poor survival after hepatectomy (97, 98). M-
CSF, together with other tumor-derived factors such as CCL2,
induces monocyte infiltration in tumors and macrophage acti-
vation toward a trophic pro-angiogenic phenotype (leading to
what is called the angiogenic switch). Thus, genetic depletion
of M-CSF in a spontaneous model of breast cancer forma-
tion (MMTV-PyMT) dramatically decreased macrophage infil-
tration and affected progression from non-malignant adenoma to
malignant carcinoma (82). Accordingly, growth of transplantable
tumors in M-CSF-deficient mice (Csf1op/Csf1op) is markedly
impaired (99).
These findings have been therapeutically exploited, showing
that M-CSFR inhibition via small molecule inhibitors or block-
ing antibodies decreases the presence of TAM in transplantable
or spontaneous tumor models and leads to a reduced tumor
angiogenesis and lymphangiogenesis (100–102). Hence, M-CSFR
blockade prevents resistance to anti-angiogenic and radiation ther-
apy (100, 103). Also in a mouse glioblastoma model, an inhibitor
of M-CSFR significantly increased survival and regressed estab-
lished tumor, which was in this case not due to TAM depletion, but
rather to a decreased expression of M2 markers and an unopposed
production of anti-tumoral GM-CSF and IFNγ (104). These data
are in agreement with the notion that M-CSF can contribute to
angiogenesis in vivo by inducing VEGF in macrophages through
the MAPK/Erk pathway (105), while GM-CSF appears to exert
opposite functions by re-educating macrophages to become anti-
angiogenic through the secretion of soluble VEGFR1 (106). Hence,
the intra-tumoral M-CSF/GM-CSF balance could determine the
M1/M2 TAM balance and consequently, the TAM effect on tumor
growth. Finally, it should be noted that M-CSF is not only capa-
ble of differentiating macrophages with pro-tumor properties, but
it also mediates the expression of activating Fc receptors, result-
ing in a tumoricidal function in the presence of tumor-targeting
mAbs (107).
CYTOKINES
The IL-4/IL-13/Stat6 pathway
IL-4 and IL-13 were shown to be crucial mediators in the stim-
ulation of invasion or immunosuppression by TAM in several
tumor types. Thus, IL-4, mainly produced by intra-tumoral CD4+
Th2 cells, modulates the TAM phenotype and induces them to
secrete EGF, leading to EGF-R-dependent invasion and metas-
tasis (108), as well as cathepsins B and S, shown to be critical
for promoting tumor growth, angiogenesis, and invasiveness in
several tumor models (109). Similarly, deficiency of IL-13, mainly
produced by tumor-infiltrating NKT cells, was shown to result
in a dominance of M1-type TAMs and resistance to metastasis
(110). Both cytokines are recognized by receptors that share the
IL-4Rα chain and activate the transcription factor Stat6, which
in turn activates M2-type genes such as arginase 1 (Arg1) and
Mrc1 (111, 112). Accordingly, Stat6-deficiency in the hematopoi-
etic compartment results in increased tumor immunosurveillance
(113). IL-4 also induces c-Myc activity in human macrophages,
which controls genes of M2 activation (Scarb1, Alox15, and Mrc1)
(114), and c-Myc regulates the differentiation and the pro-tumoral
activity of TAM (115). Furthermore, it suppresses transcription
of M1-associated genes by inhibiting Stat-1 signaling via Socs1
upregulation (116) and by inducing epigenetic changes through
upregulation of the histone demethylase JMJD3 (117).
Downstream of the Stat/Socs pathway, there is a panel of tran-
scription factors, also induced via IL-4/Stat6, that orchestrate
polarized activation. For instance, Stat6 synergizes with PPARγ
(118) to induce oxidative metabolism genes, and with KLF4 to
induce M2 genes such as Arg1 and inhibit M1 genes such as TNF
(Tnf) and iNOS (Nos2) via the sequestration of NF-κb coactiva-
tors (119). Considering that several PPAR agonists are already in
clinical use for metabolic disorders, the precise contribution of
PPARγ in TAM function and tumor development requires further
investigation (120).
The IL-10/TGFb/Stat3 pathway
The anti-inflammatory cytokines TGFβ and IL-10 are produced by
neoplastic cells, tumor fibroblasts, and tumor-infiltrating Treg and
both cytokines activate the Stat3 pathway, leading to the expres-
sion of genes associated to an M2 phenotype, such as IL-10, Tgfb1,
Mrc1 (65, 112, 121). Accordingly, systemic administration of an
anti-IL-10R antibody, in combination with local treatment with
CpG, was shown to induce a shift in resident and recruited TAMs
from the M2 into the M1-type, accompanied by tumor shrink-
age (122). Similarly, inhibition of TGFβ signaling in combination
with TLR7 ligation reprogramed the phenotype of TAMs toward
an M1 tumoricidal phenotype, and this effect was accompanied by
enhanced NF-κb nuclear translocation (123). In agreement with
these results, TGFβ signaling in TAMs induces expression of high
levels of the inactive serine/threonine kinase IRAK-M, which acts
as a potent negative regulator of TLR signaling (124). Conversely,
Stat3 can be inhibited by Socs3, as a result of IFN and TLR signaling
and Notch activation (125).
Constitutive activation of the Stat3 signaling pathway has been
observed in tumor cells as well as infiltrating cells, including
TAMs (126). Importantly, production of angiogenic factors such
as VEGF and bFGF by TAMs are induced by Stat3, and experi-
ments with mice deficient for Stat3 in the myeloid compartment,
showed that it is a crucial mediator for myeloid cell-induced tumor
angiogenesis (127).
The Stat3/NF-κb interplay
An interesting interplay exists between Stat3 and NF-κb, both
transcription factors being persistently activated in cancer and reg-
ulating a great number of genes important for cancer-promoting
inflammation [reviewed in Ref. (128)]. Stat3 has been shown
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to maintain constitutive NF-κb activation in tumor-associated
myeloid cells (129), and several inflammatory factors encoded by
NF-κb target genes, notably IL-6 released by TAMs, are impor-
tant Stat3 activators. Accordingly, a study with human cervi-
cal carcinoma lines showed that tumor-derived IL-6 and PGE2
were responsible for skewing monocyte differentiation toward a
CD14+CD163+ M2-type phenotype, and that this was reversible
upon co-incubation with Th1 cells (130). While Stat3 activation
restrains anti-tumor immune responses by antagonizing Stat1-
mediated expression of anti-tumor cytokines such as IFNγ and
IL-1 (131, 132), NF-κb activation plays a dual role: it is crucial for
inducing oncogenic inflammatory conditions, but also for gen-
erating anti-tumor responses [reviewed in Ref. (133)]. Thus, it
has been proposed that while classical NF-κb activation plays
a pro-inflammatory role in macrophages during early stages of
tumor growth, in established tumors signals such as lympho-
toxin, BAFF or CD40, can lead to alternative NF-κb activation
(134). Furthermore, NF-κb p50 homodimers have been shown
to play a key role in the orchestration of M2 responses (135).
However, the role of classical NF-κb activation in TAMs remains
controversial since inhibition of IKKβ (and therefore of NF-κB)
was shown to promote an M1-like phenotype, whereas functional
IKKβ/NF-κB activation maintained these cells in an alternative,
tumor-promoting phenotype (88).
TNF, a cytokine that classically induces NF-κb activation, plays
a role in promoting tumor progression by inducing monocytes
to produce M-CSF (136) and by stimulating, together with IFNγ,
expression of the negative costimulatory molecule PDL-1 (B7-
H1) on macrophages (137), leading to suppressed cytotoxic T-cell
responses (138). Additionally, in mouse and human colon cancer,
TNF mediates upregulation of COX-2 by macrophages, greatly
promoting carcinogenesis via PGE2 production (139, 140).
CHEMOKINES
CCL2
Expressed by macrophages, fibroblasts, endothelial, and tumor
cells, CCL2 is one of the most frequently observed chemokines in a
wide range of tumors and one of the main determinants of mono-
cyte/macrophage recruitment. In addition, CCL2 has been shown
to induce, together with IL-6, upregulation of Mrc1 in CD11b+
human mononuclear cells, suggesting a polarization to an M2-
type phenotype (141). However, the biological effect of CCL2 may
be biphasic and more related to recruitment than polarization
as suggested by a study where low-level CCL2 secretion by non-
tumorigenic melanoma cells led to modest monocyte infiltration
and stimulation of tumor formation due to increased angiogene-
sis, while high CCL2 levels were associated with massive monocyte
infiltration into the tumor mass, leading to its destruction (142).
CCL5
CCL5 is not only produced by naive T cells but also by breast
tumor cells, contributing to monocyte migration into tumor
sites (143). Interestingly, CCL5 stimulates human monocytes to
express CCL2, CCL3, CCL4, and CXCL8, all of them chemoat-
tractants for myeloid cells (144). It also stimulates the expres-
sion of the receptor CCR1 on monocytes, which is recognized
by numerous chemokines. Hence, activation of monocytes by
chemokines leads to further recruitment of more monocytes
into the tumor mass, as well as that of other leukocyte popu-
lations (145). Indeed, monocyte to macrophage differentiation
involves CCR2 downregulation and increased expression of CCR1
and CCR5 (146, 147), suggesting a multistep navigation process
whereby the initial CCR2-dependent recruitment of monocytes
is followed by a CCR1/CCR5-dependent positioning within the
tumor (148). This scenario is supported by the observation that,
in hypoxic conditions, monocytes migrate poorly in response to
CCL2 (149).
Other chemokines, including CCL3, CCL4, CCL8, and CCL22
(macrophage-derived chemokine), have been detected in ovarian
tumors (150) and high levels of CXCL8 and CCL18 have also been
found in ascitic fluids from patients with ovarian carcinoma (151).
While the presence of these chemokines in the tumor mass has
been correlated with the presence of macrophages, it still remains
to be determined whether they play a role in the recruitment
or in the maintenance of the TAM population in the neoplastic
tissues.
THE CXCR4/CXCR7/CXCL12 AXIS
CXCR4 is one of the most ubiquitously expressed chemokine
receptors and it is overexpressed in many human cancers, includ-
ing breast cancer, ovarian cancer, melanoma, and prostate cancer
[reviewed in Ref. (152)]. CXCR7, the other receptor for CXCL12
(SDF-1), is expressed by many tumor cell lines (153), and its role as
scavenger or co-receptor for CXCL12 remains in debate. Although
not expressed in normal blood leukocytes, CXCR7 expression
was shown to be upregulated upon monocyte to macrophage
differentiation, with a higher expression in M1 than in M2 phe-
notype, and to play a role in phagocytic activity (154). How-
ever, its role in TAM differentiation requires investigation. In any
case, CXCL12 can modulate monocyte-macrophage differentia-
tion toward a pro-angiogenic phenotype by upregulating VEGF
and CCL1 and down-regulating RUNX3 (155). Furthermore,
mixed M1/M2 macrophages described in colon cancer metastasis
in liver promote cancer growth via a GM-CSF/HB-EGF paracrine
loop that is enhanced by CXCL12 (156). Importantly, hypoxia dri-
ves expression of CXCL12 by EC (157) as well as of its CXCR4
receptor (158). Thus, in hypoxic regions of expanding tumors,
CXCR4 receptor levels might be increased not only to facilitate
TAM-mediated angiogenesis, but also tumor cell survival, local
invasion, and escape from the primary tumor mass (159).
Finally, it is important to keep in mind that TAM polarization is
not only affected by, but also significantly affects tumor-specific T-
cell responses [reviewed in Ref. (60)]. For example, M1-type TAM
produce cytokines (IL-6, IL-23, IL-1β, TNFα) that promote Th17
differentiation and maintain the chronic inflammatory environ-
ment (160). M2-like TAMs impair T-cell activation and effector
functions via the secretion of immune-suppressive factors such as
IL-10, PGE2, and arginase and the expression of inhibitory ligands
such as PD-L1 (B7-H1). Furthermore, they enhance recruitment
of Treg via production of CCL22 (161) and can drive differentia-
tion of Treg via TGFβ (162). TAM that originate from MO-MDSC
can also dampen T-cell responses by inducing CD4+ T-cell apop-
tosis in a Stat-1 dependent manner (163). In addition, it has been
proposed that production of CCL20 by TAMs in hypoxic regions
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may exert a “sink”-like effect by attracting NKT cells where their
viability and function are impaired (164).
TAM DIVERSITY IN TERMS OF INTRA-TUMORAL
LOCALIZATION
Tumors are complex, developing organoid structures that con-
tain several different ecosystems, such as cancer nests, peritumoral
stroma, perivascular regions, and hypoxic regions. Hence, given
the plasticity of these cells, the macrophage phenotype differs
within different areas of the same tumor and distinct functions
for these TAM subpopulations have been predicted (165).
A study by Wyckoff et al. showed that macrophages are present
in large numbers at the margins of mouse mammary tumors,
while fewer of these cells are found in association with blood ves-
sels deeper in the tumors (166). Importantly, these perivascular
TAM produce EGF, which attracts M-CSF-producing cancer cells,
resulting in a coordinated migration and intravasation of the can-
cer cells at sites of high macrophage density (166, 167). As a matter
of fact, the interaction between cancer cells, macrophages, and EC
(tumor microenvironment of metastasis or TMEM) is predictive
of metastasis formation in breast cancer patients (168). The migra-
tory nature of perivascular macrophages is confirmed in a study
by Kedrin et al., while only limited TAM migration was observed
in avascular regions (169). Along the same line, spinning disk
confocal microscopy on mammary carcinomas identified motile
and sessile TAM subpopulations in different compartments of
the tumor (170). Comparing the gene expression profile of the
migratory TAM with the more sessile cells (which have a higher
phagocytic capacity) demonstrated that most of the consensus M2
markers (171) were expressed at a higher level in the latter (172).
Accordingly, upon labeling of tumor areas proximal to perfused
vessels with Hoechst 33342 and sorting of perivascular Hoechst+
versus vessel-distal Hoechst− macrophages, the latter were shown
to express higher levels of M2 markers (173). The presence of dif-
ferentially activated macrophages within the same tumor was fur-
ther corroborated by studies discriminating between MHC-IIhigh
and MHC-IIlow TAM in different transplantable and transgenic
tumor models, which are more M1- and M2-like, respectively, and
which reside in distinctively oxygenated tumor regions (42–44).
MHC-IIlow TAM are found in the most hypoxic tumor regions
and express clearly higher levels of M2 markers such as CD124 (IL-
4Rα), stabilin-1, CD204 (SR-A), and CD206 (MMR). As a matter
of fact, molecular imaging of CD206high TAM using anti-CD206
nanobodies has been proposed as a strategy to visualize hypoxic
areas in tumors (43). Similarly, MHC-IIhigh and MHC-IIlow TAM
subsets are present in different regions of human HCC, whereby
MHC-IIlow, but not MHC-IIhigh, TAM score positive for IL-10,
suggestive of a more M2-like orientation (23).
THE INFLUENCE OF HYPOXIA ON TAM HETEROGENEITY
Considering the presence of differentially activated macrophages
in perfused and non-perfused tumor regions, hypoxia could be an
important determinant of the TAM phenotype. Indeed, most solid
tumors contain regions of chronic or cycling hypoxia (0.1–2% O2)
resulting from an abnormal vascularization in combination with
a high metabolic activity (174). Hypoxia is known to influence
the behavior of multiple stromal cell types in tumors, including
macrophages, but how oxygen tension shapes the inflammatory
response of macrophages and modulates specific differentiation
states is less well studied (175, 176).
A recent study demonstrated that the expression of the most
prominent M2 markers – CD206, CD124, and Arg1 – is not
altered in TAM subsets from better oxygenated tumors grown
in Phd2-haplodeficient mice, which display vessel normalization
(44). Rather, reduced hypoxia downregulated the expression of
several pro-tumoral genes, involved in glycolysis, angiogenesis,
and metastasis, specifically and solely in the hypoxic MHC-IIlow
TAM subset (44). These data suggest that hypoxia is not the
main driving force behind the typical M1-like/M2-like TAM acti-
vation profiles per se, but M2-like TAM preferentially home to
hypoxic areas where the pro-tumoral activities of these cells are
boosted. Formal proof for this concept came from the finding
that neuropilin-1 (Nrp-1) expression in macrophages is crucial
for the migration of these cells into hypoxic areas and for the
induction of their pro-angiogenic and immunosuppressive activi-
ties (176). Semaphorin3A, but not VEGF, was demonstrated to be
the main chemoattractant, signaling through a Nrp-1-dependent
PlexinA1/PlexinA4/VEGFR1 receptor complex. A macrophage-
specific Nrp-1 deficiency leads to an accumulation of TAM in
normoxic regions, maintaining more M1-like features such as high
NO secretion, cytotoxic activity, and T-cell stimulatory capac-
ity (176). As a result, tumors grow significantly slower, high-
lighting the importance of a hypoxia-dependent programing of
macrophages for tumor progression.
How the initial M1/M2 dichotomy of TAM subsets (inde-
pendent from intra-tumoral oxygen levels) is regulated is still
unclear. One possibility is an interaction between infiltrating
monocytes and EC, whereby EC stimulate macrophage dif-
ferentiation and an M2-like activation through M-CSF (177).
Angiopoietin-2, produced by activated EC, upregulates its recep-
tor Tie2 on macrophages and maintains these M2-like cells in
the neighborhood of blood vessels, at least for a while (178).
Blocking Ang-2 redistributes these macrophages. It is therefore
conceivable that a temporary interaction with EC instructs the
M2 phenotype (CD206high) and that these cells, upon release,
move toward the hypoxic areas where additional M2-like features
(such as angiogenic activity and immunosuppressive activity) are
strengthened.
The gene regulation of pro-tumoral factors under hypoxia is
likely to be mediated by the transcription factors HIF-1α and
HIF-2α, considering the implication of both in regulating hypoxic
adaptation in macrophages (179). In the transgenic PyMT mam-
mary tumor model, a myeloid cell-specific deficiency in HIF-1α
results in a hampered Arg1 and iNOS expression in TAM linked
with an abolished T-cell suppressive capacity (180). HIF-2α has
also been shown to regulate Arg1 and to correlate with tumor
microvessel density, and could therefore also contribute to the
pro-tumoral profile of hypoxic TAM (181, 182).
Together, these data support the notion that a reprogram-
ing of TAM toward a more M1-like phenotype is likely to
be beneficial, as monotherapy, but especially in combination
with immunotherapy. Blocking Nrp-1 seems to be a logical
approach, and monoclonal antibodies preventing Nrp-1 interac-
tion with either Semaphorin3A or VEGF have indeed proven their
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anti-tumoral potential (183). Another strategy is to apply low-
dose irradiation to the tumor, which normalizes the vasculature
and induces iNOS+ M1-like TAM that orchestrate CTL recruit-
ment into tumors by stimulating endothelial activation and Th1
chemokine production (184). Along the same line, low-dose anti-
VEGFR2 therapy causes vessel normalization and perfusion along
with an enhanced M1 polarization of TAM, allowing a better out-
come in combination with a tumor vaccine (173). More direct ways
to alter the TAM phenotype include anti-CD40 immunotherapy
(6), the combination of the TLR9 ligand CpG with blocking anti-
IL-10R antibody (122), treatment with encapsulated IL-12 (185),
or with a redox-active copper chelate (186).
TAM HETEROGENEITY: PARALLELS WITH OTHER TISSUES
Macrophage heterogeneity in response to different activation cues
has been appreciated in other tissues and may underlie different
pathological and non-pathological conditions (Figure 2).
OBESE ADIPOSE TISSUE
While in the lean state most of the macrophages present in the
adipose tissue (AT) have an anti-inflammatory M2 phenotype,
obesity induces an accumulation of a novel F4/80+CD11c+ pop-
ulation with increasing expression of M1-type genes such as TNF
and iNOS (187), leading to chronic low-grade inflammation and
insulin resistance [reviewed in Ref. (188)]. As with tumors, the
FIGURE 2 | Macrophage heterogeneity in different tissues is
reminiscent ofTAM heterogeneity. (A) Obese adipose tissue (AT). AT
macrophages switch from a more M2 activation in healthy conditions to M1
activation in obese AT. During obesity, CCL2 is involved in monocyte
recruitment to the AT and the stimulation of local macrophage proliferation.
(B) Atherosclerosis. Macrophages switch from a more M2 activation in the
healthy vessel wall to M1 in the atherosclerotic plaque. Macrophage
accumulation in the lesion is due to monocyte recruitment and local
macrophage proliferation mediated by SR-A. oxLDL is highly present and is
a main trigger of macrophage activation in the lesion. In addition, several
other types of macrophages have been described in atherosclerosis: “Mox,”
“M4” and the typical foam macrophages. (C)Maternal-fetal interface. In the
non-pregnant uterus MHC-IIlow and MHC-IIhigh macrophages are evenly
distributed over the myometrium and endometrium. In the pregnant uterus
macrophage numbers decline in the endometrium (now called decidua) and
MHC-IIlow macrophages preferentially accumulate in the myometrium.
M-CSF is involved in both the attraction of monocytes as well as
macrophage proliferation.
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contribution of recruited versus tissue-resident macrophages in
obese AT requires further investigation. It has been proposed that
AT macrophages (ATM) originate by recruitment of blood mono-
cytes (189) and progressive polarization to M1 macrophages in
response to tissue-derived signals (190). It has even been sug-
gested there may be preferential homing of a subpopulation of
monocytes to AT via recognition of the macrophage galactose
C-type-lectin 1 (MGL1) (191). However, a very recent study
in the ob/ob obese mouse model shows that a major fraction
of ATM proliferates in a CCR2-dependent manner and con-
tributes to AT inflammation independently of monocyte recruit-
ment (192). Thus, the CCL2/CCR2 axis not only is the major
chemokine/receptor pair involved in ATM recruitment [reviewed
in Ref. (193)] but also in enhancing their proliferation. Accord-
ingly, most studies show that deficiency or pharmacological inhi-
bition of CCR2 decreases ATM and protects from insulin resis-
tance (187, 194, 195). CCL2 is secreted by obesity-associated
dysfunctional adipocytes, which also upregulate IL-6 and lep-
tin, while down-regulating adiponectin [reviewed in Ref. (196)].
Interestingly, adiponectin, highly expressed by lean but not obese
adipocytes, has recently been shown to be a key factor for M2
polarization via the Stat6 pathway (197). PPARγ, induced via the
Stat6 pathway as discussed for TAM, seems to play a key role in
ATM polarization, and short-term treatment with PPARγ activa-
tors promoted infiltration of M2-type macrophages into AT with
an effect on AT morphology (198).
However, as with tumors, the M1/M2-like dichotomy is proba-
bly an oversimplification, and macrophages with a mixed M1/M2
profile have been found, particularly during the first stages of
diet-induced obesity (199). Furthermore, while ATMs are also
abundant in another metabolic disease, lypodystrophy, they have
a distinct phenotype and do not appear to be involved in the
pathogenesis of insulin resistance (200).
Interestingly, a recent study has shown that human ATMs
display activation of cancer-related pathways (201). These data
are particularly intriguing in the light of recent epidemiologi-
cal studies that have shown a clear association between obesity
and increased risk for a wide range of cancers (202). The rel-
ative contribution of endocrine, metabolic, and inflammatory
mediators in the exacerbation of tumor growth and progression
remain to be explored, as well as the influence of obesity-associated
adipocyte dysfunction on the tumor microenvironment and TAM
heterogeneity.
ATHEROSCLEROTIC LESIONS
Early studies performed in the apolipoprotein E (ApoE)-deficient
mouse model of atherosclerosis suggested that macrophages pro-
mote atherosclerosis (203). In fact, at early stages of the dis-
ease, they favor lesion progression very likely through unregu-
lated uptake of oxidized low-density lipoprotein (LDL) particles
that activate innate immune receptors and trigger the expression
of inflammatory cytokines, proteases, chemokines, and costim-
ulatory molecules. However, at later stages they may counter
lesion expansion via Mertk-mediated efferocytosis of apoptotic
bodies (204).
Recently, in murine plaques, Arg1 and Arg-2 were described as
M2 and M1 markers, respectively (205) and a transition of Arg1+
to Arg-2+ cells was described, suggesting an M2 to M1 switch
during plaque progression. Interestingly, the balance between M-
CSF to GM-CSF seems important during this process [reviewed in
Ref. (206)]. Indeed, there is growing evidence that the balance of
macrophages in the plaque is dynamic and that both macrophage
numbers and their phenotype influence plaque fate (207). There-
fore, as with tumors, macrophage heterogeneity in atherosclerosis
is an accepted concept. However, as with tumors, the M1/M2
division is an oversimplification and besides traditional M1 and
M2 macrophages, mixed M1/M2 as well as macrophages with
a totally different phenotype have been observed. For instance,
a macrophage population that shows a strong induction of the
anti-oxidant response via upregulation of the transcription fac-
tor Nrf2 has been reported in advanced lesions and called “Mox”
macrophages (208). CXCL4, present in artherosclerotic lesions
can induce so-called “M4” macrophages, with low expression
of scavenger receptors and increased levels of cholesterol efflux
transporters (209). In addition, macrophages can also internal-
ize oxidized LDLs via scavenger and oxLDL receptors, converting
into foam cells, the hallmark of the atherosclerotic lesion. In fact,
hypoxia in the lesions enhances lipid uptake by macrophages (210)
via upregulation of the of the oxLDL receptor Lox-1 in a HIF-
1α-dependent manner (211). Similarly, CXCL12 enhanced the
phagocytic capacity of CXCR7-positive macrophages observed in
lesions (154). Finally, as with ATM, a recent study showed con-
siderable local macrophage proliferation that was dependent on
expression of SR-A (212).
MATERNAL-FETAL INTERFACE
The mouse uterus contains two abundant populations of
macrophages, defined by F4/80+ MHC-IIhigh and F4/80+ MHC-
IIlow surface phenotypes that are distributed evenly between the
myometrium and the endometrium (213). Reminiscent of what
has been described in TAM, MHC-IIlow cells expressed higher lev-
els of genes associated with an angiogenic, tissue remodeling, and
repair phenotype, such as CD163, Stab1, and Mrc1. In contrast,
the MHC-IIhigh cells expressed high levels of M1-type chemokines
such as CCL5, CXC3CL1, and CCL17. During pregnancy, high lev-
els of M-CSF expression in the myometrium were shown to induce
macrophage proliferation and stimulate extravasation of Ly6Chigh
monocyte precursors in a CCR2-dependent manner (213). Impor-
tantly, M-CSF activity in the myometrium inhibited macrophage
maturation and thus, promoted the accumulation of MHC-IIlow
cells. In a remarkably comparable way, decidual macrophages in
humans comprise around 20% of leukocytes and also divide in two
subsets: CD14+ CD11chigh and CD14+ CD11clow macrophages
(214). Similar to their MHC-IIhigh murine counterparts, decidual
CD11chigh human macrophages were shown to express genes asso-
ciated with lipid metabolism and inflammation. Moreover, these
cells were more efficient in antigen processing and presentation as
well as IL-10 secretion, suggesting they may contribute to toler-
ance induction toward fetal antigens via CD1-mediated presenta-
tion of lipids (214). On the other hand, the CD11clow cells were
positive for CD209 (DC-SIGN) and CD304 (Nrp-1) (215) and
expressed genes associated with extracellular matrix formation
and tissue growth, suggesting a role in maintenance, and growth
of uterine muscle cells (214). However, both populations secreted
www.frontiersin.org March 2014 | Volume 5 | Article 127 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Van Overmeire et al. Macrophages in tumors and tissues
both pro- and anti-inflammatory cytokines (214) and thus do
not fit in the conventional M1/M2-classification. Finally, decidual
macrophages likely also contribute to parturition involving the
activation of inflammatory pathways, although the population(s)
involved remain poorly defined and it is not known whether the
constitutive IL-10 production observed during the first trimester
is reduced in late gestation [reviewed in Ref. (216)].
Thus, in parallel with what is observed in tumors, the maternal-
fetal interface is associated with an immune-suppressive, wound-
healing microenvironment that guarantees the survival of the
semi-allogeneic fetus, while ensuring uterine spiral artery remod-
eling and placental growth. However, as with tumors, there
are different macrophage phenotypes in the uterus that exert
different functions, and their numbers as well as their activa-
tion/polarization status are influenced by environmental cues –
in particular M-CSF activity levels – that vary over time and
according to the location.
CONCLUSION
This review underlines the diversity of macrophage phenotypes
and functions in tumors, which is very likely a result of their
great plasticity in response to changing environmental cues as the
tumor progresses. Furthermore, different micro-anatomical sites
within the tumor may attract and instruct different macrophage
subpopulations. As a result, macrophages may be exposed to dif-
ferent and sometimes opposing signals that underlie the different
macrophage activation states and subpopulations found within
the tumor. The importance of certain TAM subsets and their asso-
ciated molecular armamentarium for tumor progression should
not be underestimated. Indeed, it remains a remarkable observa-
tion that blocking the function of one molecule (e.g., Nrp-1) in
one cell type (the macrophage) is able to dramatically impact the
behavior of a very complex tissue such as a tumor (176). This
suggests that macrophages are indeed central players in tumor
biology and that the development of therapeutic strategies to inter-
fere with their functions is of major relevance. Directing such
therapies against the most tumor-promoting macrophage popu-
lations, while leaving anti-tumoral macrophages unharmed, seems
to be the most promising way forward. In this respect, converting
tumor-promoting M2-like TAM into anti-tumoral M1-like TAM
can be achieved via several strategies: (1) preventing macrophages
from entering hypoxic areas via Nrp-1 blockade enhances their
M1 profile and reduces pro-tumoral activities (176). Notably, anti-
Nrp-1 antibodies are currently in clinical trial for cancer therapy
(217); (2) inhibiting M2-stimulating triggers via blocking antibod-
ies or small molecule inhibitors. A non-limiting series of examples
include the use of anti-M-CSFR antibodies or inhibitors (112),
anti-IL-10R (130), COX-2 inhibitors (218), GTP cyclohydrolase
inhibitors (219), Reg3β blockade (220), and others; (3) promot-
ing M1-stimulation via triggering of TLR3 signaling (221), the
administration of IL-12 (185), histidine-rich glycoprotein (222),
Sorafenib (223), and other compounds.
Interestingly, the co-existence of distinct macrophage pheno-
types within the same tissue is also seen in non-cancerous condi-
tions, both in pathological and non-pathological settings and even
under steady state. Hence, recent transcriptomic efforts showing
a high diversity between macrophages from distinct tissues (224)
could be extended to macrophage subsets within the same tissue
and is likely to refine the concept of tissue-resident macrophages.
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